-
1
-
-
13944274479
-
Methicillin-resistant Staphylococcus aureus: An evolutionary, epidemiologic, and therapeutic odyssey
-
Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40(4), 562-573 (2005).
-
(2005)
Clin. Infect. Dis
, vol.40
, Issue.4
, pp. 562-573
-
-
Deresinski, S.1
-
2
-
-
15944389483
-
Community-associated MRSA - resistance and virulence converge
-
Chambers HF. Community-associated MRSA - resistance and virulence converge. N. Engl. J. Med. 352(14), 1485-1487 (2005).
-
(2005)
N. Engl. J. Med
, vol.352
, Issue.14
, pp. 1485-1487
-
-
Chambers, H.F.1
-
3
-
-
33644923830
-
laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States
-
Styers D, Sheehan DJ, Hogan P, Sahm DF. laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
-
(2006)
Ann. Clin. Microbiol. Antimicrob
, vol.5
, pp. 2
-
-
Styers, D.1
Sheehan, D.J.2
Hogan, P.3
Sahm, D.F.4
-
4
-
-
33747343208
-
Methicillin-resistant S. aureus infections among patients in the emergency department
-
Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
-
(2006)
N. Engl. J. Med
, vol.355
, Issue.7
, pp. 666-674
-
-
Moran, G.J.1
Krishnadasan, A.2
Gorwitz, R.J.3
-
5
-
-
33144454355
-
Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections
-
King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144(5), 309-317 (2006).
-
(2006)
Ann. Intern. Med
, vol.144
, Issue.5
, pp. 309-317
-
-
King, M.D.1
Humphrey, B.J.2
Wang, Y.F.3
Kourbatova, E.V.4
Ray, S.M.5
Blumberg, H.M.6
-
6
-
-
4744357981
-
Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers
-
Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin. Infect. Dis. 39(7), 971-979 (2004).
-
(2004)
Clin. Infect. Dis
, vol.39
, Issue.7
, pp. 971-979
-
-
Ellis, M.W.1
Hospenthal, D.R.2
Dooley, D.P.3
Gray, P.J.4
Murray, C.K.5
-
7
-
-
29944440080
-
The management of infections due to drug-resistant Gram-positive bacteria
-
Moellering RC Jr. The management of infections due to drug-resistant Gram-positive bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 24(12), 777-779 (2005).
-
(2005)
Eur. J. Clin. Microbiol. Infect. Dis
, vol.24
, Issue.12
, pp. 777-779
-
-
Moellering Jr., R.C.1
-
8
-
-
0035746948
-
Limitations of presently available glycopeptides in the treatment of Gram-positive infection
-
Ziglam HM, Finch RG. Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clin. Microbiol. Infect. 7(Suppl. 4), 53-65 (2001).
-
(2001)
Clin. Microbiol. Infect
, vol.7
, Issue.SUPPL. 4
, pp. 53-65
-
-
Ziglam, H.M.1
Finch, R.G.2
-
9
-
-
0034058528
-
Vancomycin-resistant enterococcal infections
-
Murray BE. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342(10), 710-721 (2000).
-
(2000)
N. Engl. J. Med
, vol.342
, Issue.10
, pp. 710-721
-
-
Murray, B.E.1
-
10
-
-
29244439618
-
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy
-
Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1), S40-S50 (2006).
-
(2006)
Clin. Infect. Dis
, vol.42
, Issue.SUPPL. 1
-
-
Sakoulas, G.1
Moellering Jr, R.C.2
Eliopoulos, G.M.3
-
11
-
-
2942515665
-
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy
-
Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38(12), 1700-1705 (2004).
-
(2004)
Clin. Infect. Dis
, vol.38
, Issue.12
, pp. 1700-1705
-
-
Moise-Broder, P.A.1
Sakoulas, G.2
Eliopoulos, G.M.3
Schentag, J.J.4
Forrest, A.5
Moellering Jr., R.C.6
-
12
-
-
2942558870
-
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
-
Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6), 2398-2402 (2004).
-
(2004)
J. Clin. Microbiol
, vol.42
, Issue.6
, pp. 2398-2402
-
-
Sakoulas, G.1
Moise-Broder, P.A.2
Schentag, J.3
Forrest, A.4
Moellering Jr, R.C.5
Eliopoulos, G.M.6
-
13
-
-
33846810101
-
Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections
-
Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27(2), 227-249 (2007).
-
(2007)
Pharmacotherapy
, vol.27
, Issue.2
, pp. 227-249
-
-
Drew, R.H.1
-
14
-
-
0037442373
-
Quinupristin-dalfopristin and linezolid: Evidence and opinion
-
Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36(4), 473-481 (2003).
-
(2003)
Clin. Infect. Dis
, vol.36
, Issue.4
, pp. 473-481
-
-
Eliopoulos, G.M.1
-
16
-
-
0034425844
-
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
-
Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44(12), 3408-3413 (2000).
-
(2000)
Antimicrob. Agents Chemother
, vol.44
, Issue.12
, pp. 3408-3413
-
-
Stevens, D.L.1
Smith, L.G.2
Bruss, J.B.3
-
17
-
-
19544369670
-
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections
-
Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49(6), 2260-2266 (2005).
-
(2005)
Antimicrob. Agents Chemother
, vol.49
, Issue.6
, pp. 2260-2266
-
-
Weigelt, J.1
Itani, K.2
Stevens, D.3
Lau, W.4
Dryden, M.5
Knirsch, C.6
-
18
-
-
0037364869
-
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia
-
Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25(3), 980-992 (2003).
-
(2003)
Clin. Ther
, vol.25
, Issue.3
, pp. 980-992
-
-
Wunderink, R.G.1
Cammarata, S.K.2
Oliphant, T.H.3
Kollef, M.H.4
-
19
-
-
0035112879
-
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
-
Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32(3), 402-412 (2001).
-
(2001)
Clin. Infect. Dis
, vol.32
, Issue.3
, pp. 402-412
-
-
Rubinstein, E.1
Cammarata, S.2
Oliphant, T.3
Wunderink, R.4
-
20
-
-
0242552187
-
Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia
-
Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124(5), 1789-1797 (2003).
-
(2003)
Chest
, vol.124
, Issue.5
, pp. 1789-1797
-
-
Wunderink, R.G.1
Rello, J.2
Cammarata, S.K.3
Croos-Dabrera, R.V.4
Kollef, M.H.5
-
21
-
-
0035928419
-
Linezolid resistance in a clinical isolate of Staphylococcus aureus
-
Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207-208 (2001).
-
(2001)
Lancet
, vol.358
, Issue.9277
, pp. 207-208
-
-
Tsiodras, S.1
Gold, H.S.2
Sakoulas, G.3
-
22
-
-
23744507999
-
Clinical characteristics of linezolid-resistant Staphylococcus aureus infections
-
Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am. J. Med. Sci. 330(2), 102-104 (2005).
-
(2005)
Am. J. Med. Sci
, vol.330
, Issue.2
, pp. 102-104
-
-
Peeters, M.J.1
Sarria, J.C.2
-
23
-
-
23844496128
-
Tigecycline: A new glycylcycline for treatment of serious infections
-
Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41(Suppl. 5), S303-S314 (2005).
-
(2005)
Clin. Infect. Dis
, vol.41
, Issue.SUPPL. 5
-
-
Noskin, G.A.1
-
24
-
-
23844479577
-
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam
-
Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5), S341-S353 (2005).
-
(2005)
Clin. Infect. Dis
, vol.41
, Issue.SUPPL. 5
-
-
Ellis-Grosse, E.J.1
Babinchak, T.2
Dartois, N.3
Rose, G.4
Loh, E.5
-
25
-
-
1842503232
-
Daptomycin: Another novel agent for treating infections due to drug-resistant Gram-positive pathogens
-
Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38(7), 994-1000 (2004).
-
(2004)
Clin. Infect. Dis
, vol.38
, Issue.7
, pp. 994-1000
-
-
Carpenter, C.F.1
Chambers, H.F.2
-
26
-
-
2942665465
-
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
-
Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38(12), 1673-1681 (2004).
-
(2004)
Clin. Infect. Dis
, vol.38
, Issue.12
, pp. 1673-1681
-
-
Arbeit, R.D.1
Maki, D.2
Tally, F.P.3
Campanaro, E.4
Eisenstein, B.I.5
-
27
-
-
33747365321
-
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
-
Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355(7), 653-665 (2006).
-
(2006)
N. Engl. J. Med
, vol.355
, Issue.7
, pp. 653-665
-
-
Fowler Jr, V.G.1
Boucher, H.W.2
Corey, G.R.3
|